Understand the source comparison
Best Peptides to Lose Belly Fat Fast Ranked: Mechanism Comparison
Tirzepatide (dual GLP-1/GIP) Incretin receptor agonist. Slows gastric emptying, enhances insulin sensitivity, suppresses appetite via hypothalamic signaling 20.9% mean body weight reduction at 72 weeks (SURMOUNT-1, n=2,539). Highest documented reduction in non
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tirzepatide (dual GLP-1/GIP)
- Incretin receptor agonist. Slows gastric emptying, enhances insulin sensitivity, suppresses appetite via hypothalamic signaling
- 20.9% mean body weight reduction at 72 weeks (SURMOUNT-1, n=2,539). Highest documented reduction in non-surgical intervention
- 4–8 weeks to meaningful appetite suppression; sustained throughout treatment
- Strong appetite suppression (dose-dependent)
- Gold standard for peptide-driven fat loss in 2026. Dual-pathway activation produces superior outcomes vs single GLP-1 agonists.
- Semaglutide (GLP-1)
- GLP-1 receptor agonist. Appetite suppression, delayed gastric emptying, improved beta-cell function
- 14.9% mean body weight reduction at 68 weeks (STEP-1, n=1,961)
- 2–4 weeks to appetite effect; therapeutic dose reached at 12–16 weeks
- Moderate to strong appetite suppression
- Proven efficacy with extensive safety data. Less potent than tirzepatide but more accessible and well-tolerated in most populations.
- CJC-1295 + Ipamorelin
- Growth hormone secretagogue. Elevates GH and IGF-1, increases lipolysis, preserves lean mass during deficit
- 3–7% body fat reduction in 12-week observational studies (no large RCTs). Effect size smaller than incretin mimetics
- 2–4 weeks to measurable IGF-1 elevation; fat loss visible at 8–12 weeks
- No appetite suppression; may increase appetite slightly
- Best option for lean mass preservation during fat loss. Indirect mechanism requires dietary discipline.
- Survodutide / Mazdutide
- Dual GLP-1/glucagon agonist. Combines appetite suppression with increased energy expenditure via glucagon pathway
- Phase 2 data shows 10–15% reduction at 24 weeks (not yet published in peer-reviewed journals)
- 3–6 weeks to appetite effect; energy expenditure increase within 1–2 weeks
- Moderate appetite suppression
- Promising next-generation compounds. Glucagon pathway activation may enhance visceral fat targeting beyond GLP-1 alone.
- Tesofensine
- Triple monoamine reuptake inhibitor. Increases norepinephrine, dopamine, serotonin; elevates thermogenesis and NEAT
- 10.6% mean weight reduction at 24 weeks (Phase 2, n=203)
- 1–2 weeks to appetite and energy effects
- Moderate appetite suppression + increased energy expenditure
- Non-peptide compound with peptide-like fat loss efficacy. CNS side effects (elevated heart rate, insomnia) limit tolerability in some users.
- SLU-PP-332
- ERRα/γ agonist. Upregulates mitochondrial biogenesis and fatty acid oxidation genes
- Preclinical only. 15–20% fat mass reduction in obese mice without caloric restriction
- Unknown in humans
- No appetite effect documented
- Exciting mechanism but zero human data. Theoretical potential high; clinical evidence nonexistent.